Get the Stockscreener App
2.12
3.41%
0.07
C 4 Therapeutics Inc stock is traded at $2.12, with a volume of 750.58K.
It is up +3.41% in the last 24 hours and up +40.40% over the past month.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
See More
Previous Close:
$2.05
Open:
$2.03
24h Volume:
750.58K
Relative Volume:
0.61
Market Cap:
$150.54M
Revenue:
$20.76M
Net Income/Loss:
$-132.49M
P/E Ratio:
-0.794
EPS:
-2.67
Net Cash Flow:
$-108.55M
1W Performance:
-6.19%
1M Performance:
+40.40%
6M Performance:
-38.90%
1Y Performance:
-68.26%
1-Day Range:
$1.99
$2.19
1-Week Range:
$1.99
$2.345
52-Week Range:
$1.085
$7.22
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Name
C 4 Therapeutics Inc
Sector
Industry
Phone
(617) 231-0700
Address
490 ARSENAL WAY, WATERTOWN
Compare CCCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.12 | 145.56M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Equal-Weight |
| Jan-29-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-13-23 | Upgrade | Stifel | Hold → Buy |
| Feb-24-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Apr-28-22 | Initiated | Credit Suisse | Underperform |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-10-22 | Initiated | JP Morgan | Overweight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Nov-23-21 | Initiated | BofA Securities | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-27-20 | Initiated | BMO Capital Markets | Outperform |
| Oct-27-20 | Initiated | Jefferies | Buy |
View All
C 4 Therapeutics Inc Stock (CCCC) Latest News
What are analysts’ price targets for C4 Therapeutics Inc. in the next 12 monthsWealth Building Trend Scanner For Smart Trading - jammulinksnews.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Awards $87K Worth of Stock Options in Key Employee Inducement Plan - Stock Titan
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Protara Therapeutics Grants $45K Worth of Stock Options and RSUs to Strategic New Employees - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Awards $880K Worth of Stock Options in Strategic New Employee Package - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Expands Team with Strategic Stock Grants Worth 18,200 Shares - Stock Titan
Does C4 Therapeutics Inc. stock perform well during market downturnsAdvanced Screener Report With High Returns - jammulinksnews.com
What is the risk reward ratio of investing in C4 Therapeutics Inc. stockChart Pattern Trend Scanner With Low Risk - jammulinksnews.com
Here's What Analysts Are Forecasting For C4 Therapeutics, Inc. (NASDAQ:CCCC) After Its First-Quarter Results - 富途牛牛
New Product Launches: Will They Boost C4 Therapeutics Inc. Stock in 2025Community Strategy With High Win Rate Backtested - metal.it
What makes C4 Therapeutics Inc. stock price move sharplySwing Trade Entry With Volume Triggers Released - metal.it
Published on: 2025-07-29 21:44:21 - metal.it
Is C4 Therapeutics Inc. stock overvalued or undervaluedGet timely alerts on market opportunities - jammulinksnews.com
What is the dividend policy of C4 Therapeutics Inc. stockMaximize gains with proven stock analysis - jammulinksnews.com
Is C4 Therapeutics Inc. a growth stock or a value stockRecord-setting profit potential - jammulinksnews.com
What are the latest earnings results for C4 Therapeutics Inc.Discover stocks with superior performance - jammulinksnews.com
Is it the right time to buy C4 Therapeutics Inc. stockInvest confidently with professional market insights - jammulinksnews.com
How does C4 Therapeutics Inc. generate profit in a changing economyGet daily expert analysis on top stocks - jammulinksnews.com
What are C4 Therapeutics Inc. company’s key revenue driversRapid-fire capital growth - jammulinksnews.com
Why is C4 Therapeutics Inc. stock attracting strong analyst attentionMaximize gains with data-driven trading alerts - jammulinksnews.com
When is C4 Therapeutics Inc. stock expected to show significant growthBuild wealth steadily with proven stock picks - jammulinksnews.com
Why C4 Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Stock Market Insights - beatles.ru
What analysts say about C4 Therapeutics Inc. stock outlookFree Predictions - metal.it
What analysts say about C4 Therapeutics Inc. stockExceptional stock performance - PrintWeekIndia
Is C4 Therapeutics Inc. a good long term investmentExceptional financial outcomes - PrintWeekIndia
C4 Therapeutics Inc. Stock Analysis and ForecastMarket-crushing stock picks - PrintWeekIndia
What drives C4 Therapeutics Inc. stock priceMarket-beating performance - jammulinksnews.com
C 4 Therapeutics Inc Stock (CCCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):